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Roland Seifert and Gijnter Schultz 
Uridine and uracil nucleotides are involved in the regulation of various cell 
functions. Here, Roland Seifert and Giinter Schultz review the evidence that, 
rather than by binding to purinoceptors, pyrimidine nucleotides exert their 
effects by binding to distinct pyrimidinoceptors, which are coupled to pertussis 
toxin-sensitive G proteins in human phagocytes. However, many questions 
remain to be answered: no antagonists for these pyrimidinoceptors are 
available, and binding studies have not been carried out; the receptor proteins 
and subtypes have not been characterized; and little is known about the G 
proteins and effector systems involved, or the regulation of storage and release 
of pyrimidine-nucleotides. 
Extracellular adenosine and aden- 
ine nucleotides play an important 
role in the regulation of many cell 
functions13. Adenosine binds to 
adenosine Al or adenosine A2 
receptors, leading to inhibition or 
activation of adenylyl cyclase and 
other effector systems regulated 
by guanine nucleotide binding 
proteins (G proteins)l. Extracel- 
lular adenine nucleotides bind to 
PZ purinoceptors which are sub- 
divided into Ph and PzY purino- 
ceptors according to the potency 
of purinergic agonists to activate 
cell funclions’~. In addition, cell 
type-specific purinoceptors have 
been described in mast cells and 
platelets*. 
Occupation of purinoceptors 
with agonists results in the activa- 
tion of a variety of effector sys- 
tems such as phospholipase C, 
Ca*+ channels, superoxide- (O;-)- 
forming NADPH oxidase of HL-60 
leukemic cells and n inhibition of 
adenylyl cyclaseP”. In the case of 
inhibition of adenylyl cyclase in 
rat hepatocytes and activation of 
phospholipase C and NADPH 
oxidase in HL-60 cells, purinocep- 
tors have been shown to couple 
functionally to pertussis toxin- 
sensitive G proteins4B*10*1’. 
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synergic regulation of cell 
It is known that extracellular 
uridine and uracil nucleotides are 
also effective activators of cell 
functions (Table I). However, rel- 
atively little attention has been 
paid to these observations. UTP is 
as effective as ATP in inducin 
relaxation of guinea-pig trachea l# . 
In addition, tixtracellular UTP re- 
sults in dilatation of intra- and 
extracranial arteriess15. 6y con- 
trast, uracil nucleotides and uri- 
dine also effectively induce vaso- 
contraction and an increase in the 
systemic blood pressure13J4J~~. 
These opposite effects of uracil 
nucleotides may be due to the fact 
that both vascular smooth muscle 
cells and endothelial cells are 
activated by LJTP. Thus, UTP 
may induce endothelium-depen- 
dent relaxation of blood vessels, 
presumably via the production of 
prostacyclin7*15,23. It has been sug- 
gested that the contraction of 
intracranial arteries by UTP plays 
an important role in tho patho- 
genesis of the vasospasm follow- 
ing cerebral injury, as platelets 
and brain tissue are rich sources 
of uracil nucleotides1s*21*z4~25. 
The effects of extracellular uracil 
nucleotides are not restricted to 
the vasculature. UTP induces vari- 
ous metabolic changes in perfused 
rat liver, such as stimulation of tii 
release of _@ucose, K + and $*a It; 
and mhibltlon of 4 uptake . 
365 
addition, UTP results in the mob- 
ilization of intracellular Ca*+ from 
non-mitochondrial stores and 
Ca*+ influx from the extracellular 
space in Madin-Darby canine kid- 
ney cells, Ehrlich ascites tumor 
cells, J774 macrophages and 
human neutrophils926B. In plate- 
lets and in neutrophils, uracil 
nucleotides induce aggrega- 
tion11*29j0. UTP activates O;- for- 
mation in HL-60 cells differen- 
tiated with dibutyryl cAl@O. In 
human neutrophils, UTP poten- 
tiates O;- formation and exocyto- 
sis of /%glucumnidase stimulated 
by formyl peptides%“. As pre- 
treatment with pertussis toxin 
inhibits UTP-induced O;- forma- 
tion in HL-60 cells and neutrophil 
aggregation, it is likely that the 
,effects of UTP are mediated via G 
proteinslO*‘l. UTP also enhances 
retinoic acid-induced myeloid dif- 
ferentiation of I-IL-60 cel.ls31 F-zr- 
thennore, UTP and CTP ‘have 
recently been reported to activate 
phospholipase C in cultured rat 
anterior pituitary cell$*. 
Differences between purlnergic 
and pyrimidinergic regulation 
As there is no apparent stereo- 
chemical similarity between aden- 
ine and uracil nucleotides, the 
question arises whether the ef- 
fects of the uracil nucleotides are 
mediated via purinoceptors or via 
separate pyrimidinoceptors (Fig. 
1). Forsberg et al.’ suggested that 
uracil nucleotides may bind to 
a subgroup of purinoceptors, 
whereas Martin et al.” suggested 
that certain purinoceptors also 
recognize pyrimidine bases. 
These interpretations, however, 
are not very satisfactory, as only 
the stereospecificit-- of nucleotide 
receptors for purine bases would 
justify the term ‘purinoceptors’. 
Indeed, there are several reports 
of dissociations between the ef- 
fects of extracellular adenine and 
uracil nucleotides, suggesting the 
existence of specific pyrimidino- 
ceptors (Table II). 
o There are substantial differ- 
ences in ATP- and LJTP-induced 
contractions of intracranial and 
extracranial arteries with respect 
to desensitization, potency order 
of nucleotides, effects of various 
pharmacological agents and the 
release of 5-I-IT (Refs 16, 19 and 
20). 
e In perfused rat liver, there are 
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uracil nucfeotides 
Arteries (various species) Dilatation (UTP, UDP) 13-15 
Arteries (varfous species) untorn (UTP, UOP, UMP, urkiine. CTP) l3,14,162t 
Portal vein (rat) Contraction (UTP, UDP, UMP) 16,22 
Intact organism (various species) Increase of blood prsssure (UDP. UMP, uridine, UDP-glucose) 18 
Endothelium (pig, Came) Formation of prostacyclin and inositolphosphates (UTP) 7,23 
Liver(m) lnhibitfonofOeuptake,stfmulationofglucoseoutput, K+upfakeandreleaseof K+ 
and Ga** (UTP. UOP) 
22 
~~~y~ney~lls(d~~ Ca* fnfknr. int~llul~~z+ ~~liza~n (UTP) 29 
~4m~a~(~) Ca2* inffux, fntracellufar Ca2+ mobffttation (UTP) 27 
Ehrkich ascites tumor cells (mouse) Cae+ influx, intracellular Ca*+ mobilizatfon (UTP) 28 
HL-99 cells (human) 0;-fomration,enhancementofdifferentiation(UTP) 1091 
fUeutn#nils (human, rat) PotentiationofexocytosisandO~~ formation, aggregatfon,Ca2+influx(UTP) 9,l X30 
P~~~(~rn~~ Aggregation (UDP) 29 
~~~~(~t) Fowa~nof inosftol phosphates (UTP, CXP) 32 
Most effective or potent pyrfmkfinergfo agonists are given in parentheses. 
dissociations behveen the effects 
of ATP and UTP on several metab- 
olic parametenF. 
e In HL-60 celki, the effects of 
Al? but not of IJ’W on NADPli 
oxidase or phospholipase C are 
partially resistant to inhibition by 
pertussin toxin, suggesting that 
purino- and Pyrimidinocepturs 
couple to different populations of 
G proteins~lO. In addition, ATP- 
induced activation of O;- form- 
ation in HL-60 cells is less sensi- 
tive to inhibition by activators of 
adenylyl cyclase than is the activa- 
tion induced by IJTP=‘. 
@ In neu~p~s and J774 macro- 
phages, uracil nucleotides are 
more effective activators of certain 
cell functions than the corres- 
ponding adenine nucleotides11z7. 
In J774 macrophages, ATP but not 
UTP induces a generalized in- 
crease in plasma membrane per- 
meability=. Activation of human 
neutrophils by purine nucleotides 
shows less pronounced base speci- 
ficity than the activation induced 
by pyrimidine nucleotides”. In 
addition, the effectiveness order 
of adenine nucleotides and the 
corresponding uracil nucfeotides 
to activate neutrophils is quite 
differenP. 
Stereoselectivity of 
pyrimidinergic cell activation 
One classical property of plasma 
membrane receptors is their abil- 
ity to discriminate stereoselec- 
tively various structurally related 
compounds. Figure 1 ihustrates 
the structur+activity relationship 
for pyrimidinergic activation of 
NADPH oxidase in HL-60 cells. 
The effects of pyrimidine nucleo- 
tides are ‘stereospecific with re- 
spect to the length and structure of 
the phosphate chain, to the sub- 
stitution of the ribose moiety and 
to the base. In most cell types 
examined so far, UTP is more 
effective than LIDI’, IJMP and 
uridine, and TIP and CTP are 
only relatively weak agonists. UTP 
induces dilation and contraction 
of blood vessels, whereas uridine 
exclusively induces contraction. 
These data raise the ques- 
tion whether, like adenosine and 
adenine nucleotide receptors, uri- 
dine receptors are a class of recep- 
tor different from uracil 
nucleotide receptors. In addition, 
pyrimidinergic activation shows 
differencea in the nucleotide speci- 
ficity between different cell 
types, suggesting heterogeneity 
among pyrimidinoceptors. How- 
ever, pyrimidinergic activation of 
cell functions must be studied in 
much more detail, using a broad 
variety of pyrimidine nucieotides, 
before these questions can be 
answered definitely. These tasks 
may be facilitated by the use of 
phosphorothioate analogues uf 
uracil nucleotides; this technique 
has recently been used in the 
study of pyrimidinoceptors of 
human neutrophils”*. 
Characterization of 
pyrimidinoceptors 
So far, no antagonists for pyri- 
midinoceptors are available. In 
addition, pyrimidinoceptors have 
not been characterized by binding 
studies, and the receptor proteins 
have not been identified. 
At platelet purinoceptors the 
phosphomthioate analogues of 
GTP and GDP, guanosine 5’-O-(3- 
thiotiphosphate) and guanosine 
5’-G-(2&iodiphosphate), am com- 
petitive antagonists of ADFss. 
In the case of neutrophil pyri- 
midinoceptors, the corresponding 
phosphorothioate analogues of 
UDP and IJ’lT are agonists”. Aryl- 
azidoaminopropionyl ATP and 
adenosine 5’-[o&methylene]t- 
phosphate are antagonists at cer- 
tain puiinoceptors~. By analogy, 
the corresponding uracil nucleo- 
tides may be antagonists at pyri- 
midinoceptors. 
The characterization of pyri- 
midinoceptors by receptor bind- 
ing studies will be a difficult task, 
as pyrimidine nucleotides appar- 
ently have rather low affinirf for 
their receptors. In addition, extra- 
cellular nucleotides including ura- 
cil nucleotides may rapidly be 
degraded by ectonucleotidases2, 
and recent evidence suggests that 
extracellular nucleoside triphos- 
phates are substrates for protein 
kinases catalysing the phos- 
phory]lation of several cellular pro- 
teins 5. At least for neutrophil 
nucleotide receptors, however, it is 
not likely that ~phosp~~~tion 
reactions catalysed by nucleoside 
diphosphate kinase are involved 
in regulation of cellular functions 
by extracellular purine and pyri- 
midine nucleotidesii. 
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Uridine 5’-[ar-35S-thio]triphos- 
phate and uridine 5’-[fl-35S-thio]- 
~phosphate may be useful ligands 
for binding studies at certain pyri- 
midinoceptors, by analogy with 
the use of adenosine 51-[&% 
thioltriphosphate and adenosine 
5’-[35Sthio]diphosphate for the 
characterization of purinocep- 
tar?‘. Another possible approach 
would be to use stereospecific 
labelling of plasma membrane pro- 
teins to identify and to isolate the 
receptor proteins. Inte~stin~y, 
Tauber et al.ssobserved that labelled 
uridine and UTP covalently bind 
to specific plasma membrane pro- 
teins in rat liver. It remains to be 
determined, however, whether 
covalent binding of uridine and 
uracil nucleotides to proteins is 
causally linked to pyrimidinergic 
activation of cell functions, as acti- 
vation of NADPH oxidase in 
HL-60 cells by UTP is a reversible 
processlO. 
Desensitization of 
pyrimidinoceptors and receptor 
synergism 
~sensitization of pyrimidino- 
ceptors has been shown for sev- 
eral cell types. In myeloid cells the 
mechanisms ~de~~ng desen- 
sitization of pyrimidinoceptors 
may be similar to those of formyl 
peptide receptors: cytochalasin B 
367 
Nucleotlde (-log M) 
b:SbuchwmsofUTPderivaMnssandATP.UTPwasthemuFteffectiveandmastpotentof 
thepydmtdtnenucreorides testt.?d(t~5cur). Deaq4TPfdeo~~@~Wnsfeadof~~ 
Al~lers~~~~~CTPla~gmupinstead4fkg~Rin~~~ering 
papifion 4j, ‘TTP MWhYl instead of hydmen, C, in pynmtdine rtng position 5) and UDP 
flacks the &mine1 phosphate gtvup, 0) am very paor ,+&om of NADpn ox&se. 
PyrtmBceeptom in Ht-80 cells there&e sfemoseWW& mcvgnke the base, the 
rii moiety and tk potyphosphate chatn of pylimidine nucteot&s. fSw Ref. 10 for 
experimental details.) 
potentiates the stimulatory effects 
of both formyl peptides and UTP 
sion of plasma membrane recep- 
on O;- formation*“*3g, probably 
tom In human neutrophils and 
HL-60 cells cross-desensitization 
by preventing receptor sequestra- 
tion and by enhancing the expres- 
between purinoceptors and pyri- 
midinoceptors occurslo*‘l. These 
TABLE II. Differences between the effects of extracellular purtne and p~mi~ne nudeotMes on cett functions 
ParaflWMr Puffne nucleotides Pyrlmldlne nucleotldes Ref. 
Rabbit ear artery. wntxaotfon 
Pretreatment with [a,@CH&ITP 
Rabbit basilar artery, contraction 
Treatment with p~~~i~ or react& btue B 
Pretreatment with ATP[YS] 
Pretreatment with UTP 
~~~I~~f~U~~~ wdlfatatfon 
Antagonism by methysergfde or phentolamine, CHT 
release 
Perfur& rat liver, varfoua metabolfc changes 
0s consumption 
Glucose output after withdrawal 
Initial K+ uptake 
K+ release after wlthdrawal 
Ca*+ release 
HL-MJ cells, CXs-f~~f~tatkfa 
Pertussis toxin sensitivity 
Sensitivity to inhibition by CAMP-increasing agents 
Humah ueutrophlle, ~~~~on of o;- foraatfon 
Sase specificity 
Effectiveness order 
J774 maorophages, Cax+ inffux 
Generalized increase in plasma membrane permeabilitV 
desensttfzation 
no effect 
desensitization 
no effect 
yes 
19 
potent&ion/partial desensifbafion 
20 
e~~rn~t 
no effect 
desensitization 
14 
no 
incmase 
insist 
no 
more effective 
decrease 
Yes 
profonged 
Yes 
less effective 
22 
partial 
more resistant 
complete 
more sensitive 
ITP > ATP = GTP UTP > CTP. TTP inactive 
ATP[yS] > ATP 1 ADP > UTP[yS] > UTP = UDP[pS] = 
(np)-ATP@S], ADP[ftS] inactive @p)-UTP[@], UDP inactive 
10 
11 
Yes 
27 
no 
[a,&CNslATP, adenosine 5’.[o;B-methylene]hiphosphate; ATP[yS], sdenosine 5’-O-[3-thiotrtphosphatel; ADPI@], adenosine 5’.0[2- 
thiocliphosphate]; (xp)-ATPMS], np-diastereomer of adenosine 5’.0[2-thiotriphosphate]; UTP[YS], uridine 5’.0[3-thiotriphwphate]; UDP[@S]. 
u&fine 5’-~[~t~~~ph~~te]; (np)-tITP[#tB], (~)~~s~r~rn~ of u&tine ~-~~-thio~p~~e] 
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to guanine nucleotides. The func- 
tional similarities between pur- 
inoceptors and pyrimidinoceptors 
make adenylyl cyclase, phospho- 
lipase C and Ca2’ and K+ channels 
likely candidates as pyrimidiner- 
gic effector systems. 
Storage and release of pyrimidine 
nucleotides 
Only limited information is 
available concerning the storage 
and regulation of release of uracil 
nucleotides. Uracil nucleotides are 
stored in granules of platelets and 
may be released from these cells 
upon stimulationz4. Uracil nucleo- 
tides are also present at concentra- 
tions of up to 0.7 umole g-l fresh 
weight in liver, kidney and 
brain=. By analogy with adenine 
nucleotides, uracil nucleotides 
may be released from cells under a 
variety of patholo~c~ conditions 
such as trauma, hypoxia and in- 
flammation2. Because uracil nu- 
cleotides activate cell functions in 
the concentration range 1 HAM to 
1 mM, pyrimidinergic regulation is 
likely to take place in t&o. The 
question of whether there is a 
more specific and controlled re- 
lease of UTP into the extracellular 
space from intracellular stores of 
neurons, chromaffin or mast cells 
or from the cytosol deserves fur- 
ther investigation. 
fomyl paWee UTP 
cs2+ 
~.2~~~~~~~~~~e~h~an 
m~&~Hcetts. Ce, cym&ak~ f3; DG. diacyfg&xW: G, Gptotein; FP, fot7nylpqtide 
m I&, ino&of t,4,M&phosphate; PKC, protein kinasa C: PLC, phospholipase 
C; PT. perto& toxin; PU, pwtmcspkx PY, pyrimidinw~. There an, several 
fon&mat similadtks in the eff&& of kxmyl pqtides and purine and pydmidine 
of Ca2+, are 
~,~~~~ deseosftization 
andareinhfbitedbyanincraesainlfreintraaeiu~aDncentratianofcaMP(Flefs4-1 1).In 
add&on, their effeds am inhibited bypedu&s loxIn which ADP-dbasytates G pmteins, 
than&y htn&WMy unwupling mceph@vm t!mir e-r systems~io~ ’ ? Activation of 
IS achievtxi erther di~,~~~~~~t~ 
- 
~~~~~-es~~e 
~thetdheeffedsofUTParemoresuscepfibietoinhibibbnbyperhrssisfoxinandan 
inuease in CAMP than those of ATP and that the efkctiveness order of adenine 
. ZiiWwlt
uckoMe3 aod the mnaqonding uracil nudeotides to activate ceil fonctions is quite 
rar’. Fudhennom, ATP and UTP potent&e the efkts of t&my1 peptide&‘? 
results do not necessarily argue 
against the existence of different 
types of nucleotide receptor, but 
rather may support the concept 
that the two &asses of receptor are 
cl&y related functionally. 
Different classes of intercellular 
signal molecule interact synergis- 
ticall 
Y 
to activate human neutro- 
phils l. This is also the case for the 
interaction of pyrimidinoceptors 
and receptors for formyl peptides, 
platelet activating factor and 
leukotriene B4 to activate O;- 
formation, exocytusis and aggre- 
gation in human myeloid sellss-l*. 
The mechanisms underlying sy- 
nergistic interaction of these re- 
ceptors may be complex. They 
may involve increases in the affin- 
ity of receptors, additive or syner- 
gistic activation of different pools 
of G proteins and amplified gen- 
eration of intracelh&r signal mol- 
ecules, such as diacylglycerol, 
Ca” and arachidonic acid. Study- 
ing the interactions of extracellu- 
lar pyrimidine nucleotides with 
Other intercelhtlar signal mol- 
ecules in non-myeloid ccl! types 
should help elucidate the role 
of pyrimidines in regulating cell 
function. 
Functional coupling to G prokins 
and effector systems 
The characterization of the 
coupling of pyrimidinoceptors to 
G proteins is another important 
task. NADPH oxidase is coupled 
to pyrimidinoceptors via pertus- 
sis toxin-sensitive G proteinslo. 
By analogy with purinergic activ- 
ation, pyrimidinergic activation of 
phospho~pase C in HL-60 cells is 
also likely to be pertussis toxin 
sensitives. However, it is not 
known whether, as is the case for 
NADPH oxidase’O, purinergic and 
pyrimidinergic activation of phos- 
pholipase C in these cells show 
differential pertussis toxin sen- 
sitivity. 
In pertussis ~xin-in~nsitive 
signal transduction systems, the 
interaction of pyrimidinoceptors 
with G proteins will be more 
difficult to demonstrate; a pos- 
sible approach would be to test 
the sensitivity of agonist binding 
q q El 
The mechanism by which extra- 
cellular pyrimidine nucleotides 
regulate cell functions shows many 
properties characteristic of recep- 
tor-mediated processes. These in- 
clude stereospecificity for agonists, 
reversibility and desensitization 
of activation, involvement of G 
proteins, the generation of intra- 
cellular signal molecules and acti- 
vation of cellular effector systems. 
There is substantial indirect 
evidence for the existence of 
pyrimidinoceptors distinct from 
purinoceptors. 
Information so far available 
suggests that many cell types pos- 
sess pyrimidinoceptors and that 
these receptors are heterogeneous. 
Figure 2 summarizes the mechan- 
isms involved in ?~id~e~ic 
activation of human myeloid cells. 
HL-60 cells and human neutro- 
uhils are useful model svstems 
‘to study the pyrimidinergi: regu- 
lation of cell functions. However, 
the physiological relevance of 
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pyrimidinergic regulation of cel- 
lular functions is as yet poorly 
undersrood, owing to the lack of 
information on how the release of 
pyrimidine nucleotides is con- 
trolled. 
The development of potent and 
selective agonists and antagonists 
for pyrimidinoceptors is essential 
to characterize these receptors, 
and may provide a novel approach 
to intervene in various patho- 
logical states such as inflam- 
matory processes and vascular 
diseases. 
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John S. Laze and Robert R. Bahnson 
The poor therapeutic index and limited efficacy of current cancer chemother- 
ap~~c agents represent an ~mpo~ant pha~acolo~ca~ prab~m. Athough 
there has been a significant increase in our understandjng of the nnechanisms 
by which anticancer drugs kill mammalian cells, identification of new, 
effective anticancer agents during the last decade has been exceeding slow. 
Thus, attention has focused on understanding the causes of drug resistance and 
on either sassing tumor cells to existing anticunc~ agents using what could 
be called ‘ckemoenhancers’, or protecting non-malignant tissues against 
serious untoward effects using ‘ckemoprotectors’. John Laze and Robert 
Bahnson review recent strategies attempting to modulate the activity of 
antineopiastic drugs. 
When demand exceeds supply, 
people look for ways to increase 
the usefulness of the existing sup 
ply. So it currently is in cancer 
research: there are many malig- 
nancies that do not respond to 
chemotherapy and too few ex- 
citing novel drugs to test. This, 
combined with an elevated under- 
standing of the molecular basis of 
resistance to anticancer drugs, has 
kindled interest in identifying 
and developing pharmacological 
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modulators of existing cancer 
chemotherapeutic agents to im- 
prove their therapeutic indices. 
Two classes of modulator are 
being examined: chemoenhan- 
cers, which would sensitize tum- 
or cells; and chemoprotectors, 
which would selectively protect 
non-ma~~ant tissue. 
To be a successful chemo- 
enhancer or chemoprotector, an 
agent must exhibit little toxicity 
itself; many such agents have no 
anticancer activity at all and some 
have other useful pharmacological 
properties. The clinically success- 
ful combination of methotrexate 
with leucovorin (folinate} pro- 
vides an important precedent for 
the chemoprotective approach; 
cisplatin, currently one of the 
most popular anticancer drugs, 
